Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of DCC-2618 in Advanced GIST
NCT07618377Phase 1Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ripretinib in gastrointestinal stromal tumor (GIST), sponsored by Ono Pharmaceutical. Primary endpoint: Adverse event at 2 years. Started Jul 2026; status: recruiting.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT07618377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618377.